Celltex Therapeutics

Celltex Therapeutics, founded in 2011, is a private company providing autologous adult stem cell banking and therapeutic administration services. Its core business involves extracting a patient's adipose-derived mesenchymal stem cells, expanding them to hundreds of millions in its cGMP facility, cryopreserving them, and then providing them back to the patient for therapeutic infusions administered by third-party physicians. The company reports over 10,000 therapies administered and focuses on a direct-to-consumer model for conditions like chronic pain, autoimmune diseases, and injury recovery. Celltex operates in a regulatory gray area, offering its cells as a patient-specific biologic rather than an FDA-approved drug.

Proprietary closed-system platform for isolation, expansion, and cryopreservation of autologous adipose-derived mesenchymal stem cells (MSCs).

Competes with a large and fragmented market of direct-to-consumer stem cell clinics offering similar autologous services, often with less sophisticated manufacturing. Also faces indirect competition from biopharma companies developing allogeneic, off-the-shelf MSC therapies that are pursuing formal FDA approval for specific indications, which could eventually offer a more standardized and potentially insured alternative.